These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 17168361)

  • 21. Consolidation radiotherapy may improve outcomes in people with Hodgkin's disease achieving complete remission after combination chemotherapy.
    Specht L
    Cancer Treat Rev; 2004 Aug; 30(5):479-82. PubMed ID: 15245780
    [No Abstract]   [Full Text] [Related]  

  • 22. Survival in Hodgkin's disease patients--report of 25 years of experience at the Milan Cancer Institute.
    Bonadonna G; Viviani S; Bonfante V; Gianni AM; Valagussa P
    Eur J Cancer; 2005 May; 41(7):998-1006. PubMed ID: 15862748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of a modified Stanford V regimen in patients with advanced Hodgkin's lymphoma.
    Hohaus S; Di Febo A; Storti S; Teofili L; Voso MT; Leone G
    Haematologica; 2004 Jun; 89(6):751-2. PubMed ID: 15194545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Ten-year outcomes of lymphogranulomatosis treatment according to the protocol MOPP-ABVD+radiotherapy].
    Pivnik AV; Rastrigin NA; Moiseeva TN; Lutsenko IN; Dudarova RG; Shavlokhov VS; Efimov IV; Kozhurin SV; Shitareva IV; Gemdzhian EG; Tsyba NN; Kolosova LIu; Melikian AL; Skidan NI; Pan'shin GA; Sotnikov VM; Dotsenko PV; Nechistiuk AV
    Ter Arkh; 2006; 78(8):57-62. PubMed ID: 17078219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [ABVD chemotherapy for Hodgkin lymphoma at a single institute].
    Ohshima R; Motomura S; Hashimoto C; Miyazaki T; Ito S; Takasaki H; Hyo R; Koharazawa H; Takemura S; Yamazaki E; Fujimaki K; Tomita N; Fujita H; Fujisawa S; Harano H; Kanamori H; Ishigatsubo Y
    Rinsho Ketsueki; 2010 Dec; 51(12):1756-61. PubMed ID: 21258185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Super-acute onset of tumor lysis syndrome accompanied by hypercytokinemia during treatment of Hodgkin's lymphoma with ABVD chemotherapy.
    Suzuki T; Takeuchi M; Saeki H; Yamazaki S; Koga H; Abe D; Nishimura M; Nakaseko C; Nakasa H; Nakamura H; Ariyoshi N; Kitada M
    Clin Ther; 2010 Mar; 32(3):527-31. PubMed ID: 20399989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective study of combined modality treatment or radiotherapy alone in the management of early-stage adult Hodgkin's disease.
    Yildiz F; Zengin N; Engin H; Güllü I; Barista I; Caglar M; Ozyar E; Cengiz M; Gürkaynak M; Zorlu F; Caner B; Atahan IL; Tekuzman G
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):839-46. PubMed ID: 15465201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.
    Meyer RM; Gospodarowicz MK; Connors JM; Pearcey RG; Bezjak A; Wells WA; Burns BF; Winter JN; Horning SJ; Dar AR; Djurfeldt MS; Ding K; Shepherd LE; ;
    J Clin Oncol; 2005 Jul; 23(21):4634-42. PubMed ID: 15837968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Etoposide, vinblastine, adriamycin and prednisolone (EVAP) combination chemotherapy as first-line treatment for Hodgkin's disease.
    Raina V; Sharma A; Mohanti BK; Kumar R; Dawar R; Rath GK
    Natl Med J India; 2003; 16(4):199-203. PubMed ID: 14606767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease.
    Brosteanu O; Hasenclever D; Loeffler M; Diehl V;
    Ann Hematol; 2004 Mar; 83(3):176-82. PubMed ID: 15064867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.
    Federico M; Luminari S; Iannitto E; Polimeno G; Marcheselli L; Montanini A; La Sala A; Merli F; Stelitano C; Pozzi S; Scalone R; Di Renzo N; Musto P; Baldini L; Cervetti G; Angrilli F; Mazza P; Brugiatelli M; Gobbi PG;
    J Clin Oncol; 2009 Feb; 27(5):805-11. PubMed ID: 19124807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Twenty-year disease and treatment-associated mortality rates of patients with Hodgkin lymphoma of clinical stages IIIB and IV prospectively treated with 3-month anthracycline-based chemotherapy followed by extended high-dose radiation.
    Sénécal D; Jais JP; Desablens B; Berthou C; Casassus P; Moles MP; Delwail V; Gastinne T; Colonna P; Andrieu JM
    Cancer; 2008 Feb; 112(4):846-55. PubMed ID: 18072259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.
    Noordijk EM; Carde P; Dupouy N; Hagenbeek A; Krol AD; Kluin-Nelemans JC; Tirelli U; Monconduit M; Thomas J; Eghbali H; Aleman BM; Bosq J; Vovk M; Verschueren TA; Pény AM; Girinsky T; Raemaekers JM; Henry-Amar M
    J Clin Oncol; 2006 Jul; 24(19):3128-35. PubMed ID: 16754934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
    Gobbi PG; Broglia C; Levis A; La Sala A; Valentino F; Chisesi T; Sacchi S; Corbella F; Cavanna L; Iannitto E; Pavone V; Molica S; Corazza GR; Federico M
    Clin Cancer Res; 2006 Jan; 12(2):529-35. PubMed ID: 16428496
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results.
    Bonadonna G; Bonfante V; Viviani S; Di Russo A; Villani F; Valagussa P
    J Clin Oncol; 2004 Jul; 22(14):2835-41. PubMed ID: 15199092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease.
    Hudson MM; Krasin M; Link MP; Donaldson SS; Billups C; Merchant TE; Kun L; Billet AL; Kaste S; Tarbell NJ; Howard S; Friedmann AM; Hurwitz CA; Young JA; Marcus KC; Rai S; Cowan T; Weinstein HJ
    J Clin Oncol; 2004 Nov; 22(22):4541-50. PubMed ID: 15542805
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term follow-up of salvage radiotherapy in Hodgkin's lymphoma after chemotherapy failure.
    Campbell B; Wirth A; Milner A; Di Iulio J; MacManus M; Ryan G
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1538-45. PubMed ID: 16125872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis.
    Visco C; Nadali G; Vassilakopoulos TP; Bonfante V; Viviani S; Gianni AM; Federico M; Luminari S; Peethambaram P; Witzig TE; Pangalis G; Cabanillas F; Medeiros LJ; Sarris AH; Pizzolo G
    Eur J Haematol; 2006 Nov; 77(5):387-94. PubMed ID: 16879607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Over 30-year experience of Polish Pediatric Leukemia/Lymphoma Study Group for treatment of Hodgkin's disease in children and adolescents: improvement curability and decrease of serious complications].
    Balwierz W; Moryl-Bujakowska A; Depowska T; Klekawka T; Stanuch H; Matysiak M; Sopyło B; Kołakowska-Mrozowska B; Krenke K; Chybicka A; Raś M; Sońta-Jakimczyk D; Moszant A; Wachowiak J; Kaczmarek-Kanold M; Kowalczyk J; Odój T; Balcerska A; Drozyńska E; Wysocki M; Kołtan A; Krawczuk-Rybak M; Stolarska M
    Przegl Lek; 2004; 61 Suppl 2():33-9. PubMed ID: 15688474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group.
    Arakelyan N; Berthou C; Desablens B; de Guibert S; Delwail V; Moles MP; Quittet P; Jais JP; Colonna P; Andrieu JM;
    Cancer; 2008 Dec; 113(12):3323-30. PubMed ID: 18988286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.